Intratumoral heterogeneity may be responsible for chemotherapy resistance in patients with small cell lung cancer
Small cell lung cancer (SCLC) accounts for 14% of all lung cancers and is often rapidly resistant to chemotherapy, resulting in poor clinical outcomes. Treatment has changed little for decades, but a study at The University of Texas MD Anderson Cancer Center found that chemotherapy results in increased heterogeneity within the tumor, leading to the evolution of multiple resistance mechanisms.
The research team, led by Lauren Averett...
RNA editing study shows potential for more effective precision cancer treatment
If there is one thing all cancers have in common, it is they have nothing in common. A multi-center study led by The University of Texas MD...
TMC3 Founding Institutions Chart Unprecedented Course for Life Sciences with New Research Campus
Founding TMC3 institutions – Texas Medical Center (TMC), Baylor College of Medicine, Texas A&M University Health Science Center, The University...
Size, structure help poziotinib pose threat to deadly exon 20 lung cancer
A drug that failed to effectively strike larger targets in lung cancer hits a bulls-eye on the smaller target presented by a previously untreatable form of the disease, researchers at The University of Texas MD Anderson Cancer Center report in Nature Medicine.
Their research provided the scientific underpinning for clinical trials under way of the drug poziotinib against non-small-cell lung cancer that has a specific alteration...
Study may explain why some triple-negative breast cancers are resistant to chemotherapy
Triple-negative breast cancer (TNBC) is an aggressive form of the disease accounting for 12 to 18 percent of breast cancers. It is a scary...
MD Anderson Hosts Free Skin Screenings in Bay Area, Texas Medical Center
The University of Texas MD Anderson Cancer Center will host free skin cancer screenings from 10 a.m. – 1 p.m. on Saturday, May 5 at two of...
MD Anderson researcher elected to American Academy of Arts and Sciences
Richard D. Wood, Ph.D., professor at The University of Texas MD Anderson Cancer Center, has been elected as a member of the American Academy...
Combination therapy strengthens T cells in melanoma pre-clinical study
A pre-clinical study of two drugs designed to boost T cell performance, has revealed the agents, when give in combination, may enhance the...
Boosting T cell “memory” may result in longer-lasting and effective responses for patients treated with checkpoint blockade immunotherapies
Just like people, some T cells have excellent memories. These subtypes known as memory T cells may explain why some immunotherapies are more...
Prom Comes to Teen Cancer Patients, in the Hospital
Special Note: All prom events are open to media, including the dress and tux selection, and hair and makeup appointments.
The...
Precancerous colon polyps in patients with Lynch syndrome exhibit immune activation
Colon polyps from patients with Lynch syndrome, a hereditary condition that raises colorectal cancer risk, display immune system activation...
First-in-human clinical trial of new targeted therapy drug reports promising responses for multiple cancers
A phase I, first-in-human study led by The University of Texas MD Anderson Cancer Center reveals for the first time, an investigational drug...
Polo on the Prairie slates country music star Ryan Bingham
Country music fans and polo enthusiasts alike are expected at the 32nd annual Polo on the Prairie, an annual polo match and fundraising event...
Findings from breast and gynecological cancer study may have potential for future clinical applications
Researchers from The University of Texas MD Anderson Cancer Center have found a startling amount of new information about molecular features...
Study of gene enhancers sheds light on how some cancers form and spread
At the heart of any cancer diagnosis or treatment are cells. If one thinks of the cell components controlling gene activation as a Russian...